New Prospects for Prenatal Diagnosis and Fetal Therapy

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Obstetrics & Gynecology".

Deadline for manuscript submissions: closed (31 January 2021) | Viewed by 30844

Special Issue Editor


E-Mail Website
Guest Editor
Prenatal Diagnostic Ultrasound Unit, The Helen Schneider Women’s Hospital, Rabin Medical Center, Beilinson Campus, Petach-Tikva, and The Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel
Interests: prenatal diagnosis; fetal malformations; first trimester scan; Congenital anomalies of the kidneys and urinary tract; Urogenital malformations; gastro-intestinal malformations; fetal cardiac surveillance

Special Issue Information

Dear Colleagues,

Prenatal diagnosis is a dynamic field that has greatly developed over the past few decades due to technological advances in fetal imaging and genetic analysis. Despite advances in prenatal diagnosis and fetal imaging, a substantial proportion of malformations remain undiagnosed until after birth. Diagnosis of fetal malformations prior to delivery enables prenatal counseling by the relevant multidisciplinary teams, fetal surveillance, intra-uterine intervention if required, and scheduled delivery in terms of gestational age and location for optimal perinatal management. A morphologically oriented sonographic approach that aims to provide a detailed fetal phenotype has clinical relevance for targeted and accurate genetic analysis and perinatal care.

Future challenges in prenatal diagnosis concerning the future health of fetuses with anatomical aberrations include the identification of prenatal maternal and environmental risk factors, sonographic features and their correlation with post-natal outcome for better prognostication of short- and long-term outcomes, pre- and post-natal medical interventions to reduce complications and improve long-term outcomes, and measures for optimizing fetal surveillance and reducing associated morbidity and mortality.

This Special Issue aims to present a collection of original research papers and review articles that discuss the current state-of-the-art, address existing knowledge gaps, and focus on improving the diagnosis and treatment of fetal malformations.

Dr. Sharon Perlman
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Prenatal diagnosis
  • Fetal malformations
  • Fetal ultrasound
  • Fetal MR imaging
  • Short- and long-term Outcome of fetal malformations
  • Genetic counseling

Published Papers (10 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 1448 KiB  
Article
Prenatal Screening of Trisomy 21: Could Oxidative Stress Markers Play a Role?
by Angelika Buczyńska, Iwona Sidorkiewicz, Sławomir Ławicki, Adam Jacek Krętowski and Monika Zbucka-Krętowska
J. Clin. Med. 2021, 10(11), 2382; https://doi.org/10.3390/jcm10112382 - 28 May 2021
Cited by 6 | Viewed by 2500
Abstract
Despite significant progress in trisomy 21 (T21) diagnostic tools, amniocentesis is still used for the confirmation of an abnormal fetal karyotype. Invasive tests carry the potential risk of miscarriage; thus, screening biomarkers are commonly used before undergoing invasive procedures. In our study, we [...] Read more.
Despite significant progress in trisomy 21 (T21) diagnostic tools, amniocentesis is still used for the confirmation of an abnormal fetal karyotype. Invasive tests carry the potential risk of miscarriage; thus, screening biomarkers are commonly used before undergoing invasive procedures. In our study, we investigated the possible application of oxidative stress markers in the prenatal screening of trisomy 21. The DNA/RNA oxidative stress damage products (OSDPs), advanced glycation end (AGE) products, ischemia-modified albumin (IMA), alfa-1-antitrypsin (A1AT), asprosin, and vitamin D concentrations were measured in both maternal plasma and amniotic fluid in trisomy 21 (T21) and euploid pregnancies. The obtained results indicated increased levels of DNA/RNA OSDPs and asprosin with simultaneous decreased levels of vitamin D and A1AT in the study group. The diagnostic utility of the plasma measurement based on the area under the received operative characteristic (ROC) curve (AUC) calculation of asprosin (AUC = 0.965), IMA (AUC = 0.880), AGE (AUC = 0.846) and DNA/RNA OSDPs (AUC = 0.506) in T21 screening was demonstrated. The obtained results indicate a potential role for the application of oxidative stress markers in the prenatal screening of T21 with the highest screening utility of plasma asprosin. Full article
(This article belongs to the Special Issue New Prospects for Prenatal Diagnosis and Fetal Therapy)
Show Figures

Figure 1

9 pages, 1054 KiB  
Article
Defining the Normal Growth Curve of Fetal Fractional Limb Volume in a Japanese Population
by Satoru Ikenoue, Yohei Akiba, Toyohide Endo, Yoshifumi Kasuga, Kazumi Yakubo, Ryota Ishii, Mamoru Tanaka and Daigo Ochiai
J. Clin. Med. 2021, 10(3), 485; https://doi.org/10.3390/jcm10030485 - 29 Jan 2021
Cited by 4 | Viewed by 1907
Abstract
Fetal fractional limb volume is a useful measure for predicting birth weight and newborn adiposity; however, a normal growth curve has been reported solely in the United States. As the birth weight of neonates in Japan is significantly lower than that in the [...] Read more.
Fetal fractional limb volume is a useful measure for predicting birth weight and newborn adiposity; however, a normal growth curve has been reported solely in the United States. As the birth weight of neonates in Japan is significantly lower than that in the US, fetal fractional limb volume is likely to be smaller in the Japanese population. This study aimed to define the normal growth curve of fractional arm volume (AVol) and thigh volume (TVol) in the Japanese population. Ultrasound scans of 453 AVol and TVol pairs were obtained; each AVol and TVol percentile at each gestational age was calculated. The measured AVol and TVol at each gestational week were also converted to z-scores based on a previous report. The growth curves increased linearly until the second trimester and exponentially in the third trimester. Linear regression showed a significant negative correlation between gestational age and AVol and TVol z-scores. The growth pattern of fetal fractional limb volume in the Japanese population is consistent with, but smaller than, that reported in the US; this difference becomes greater as the gestational age progresses. Full article
(This article belongs to the Special Issue New Prospects for Prenatal Diagnosis and Fetal Therapy)
Show Figures

Figure 1

8 pages, 753 KiB  
Article
The Significance of Apolipoprotein E Measurement in the Screening of Fetal Down Syndrome
by Angelika Buczyńska, Iwona Sidorkiewicz, Sławomir Ławicki, Adam Krętowski and Monika Zbucka-Krętowska
J. Clin. Med. 2020, 9(12), 3995; https://doi.org/10.3390/jcm9123995 - 10 Dec 2020
Cited by 7 | Viewed by 1911
Abstract
Prenatal screening for Down syndrome (DS) is based on both noninvasive and invasive methods. Noninvasive, cell-free fetal DNA genetic tests are expensive, whereas biochemical methods remain imprecise. Amniocentesis is the most frequently used invasive diagnosis procedure, characterized by 99.8% diagnostic efficiency and less [...] Read more.
Prenatal screening for Down syndrome (DS) is based on both noninvasive and invasive methods. Noninvasive, cell-free fetal DNA genetic tests are expensive, whereas biochemical methods remain imprecise. Amniocentesis is the most frequently used invasive diagnosis procedure, characterized by 99.8% diagnostic efficiency and less than 1% risk of miscarriage. The aim of this study was to evaluate the screening value of apolipoprotein E (ApoE) as a potential noninvasive biomarker for prenatal DS assessment. This study was conducted on a group of female patients who decided to undergo routine amniocentesis between the 15th and 18th week of pregnancy at the Department of Reproduction and Gynecological Endocrinology of the Medical University of Bialystok, Poland. For the purpose of this study, 20 women with DS fetuses were selected as the study group, and 20 healthy pregnant women with euploid fetus karyotypes as the control group. The plasma levels of ApoE were significantly higher in the study group compared to healthy subjects (p < 0.05). The area under the receiver operating characteristic (ROC) curve was 0.978 (p < 0.001), with the cut-off set to 1.37 mg/mL, which was characterized by 80% of sensitivity and 100% of specificity. The high sensitivity and specificity demonstrate the screening utility of maternal ApoE concentration in prenatal fetal DS screening. Full article
(This article belongs to the Special Issue New Prospects for Prenatal Diagnosis and Fetal Therapy)
Show Figures

Figure 1

10 pages, 5434 KiB  
Article
Outcomes after In Utero Myelomeningocele Repair Based on Delivery Location
by Eric P. Bergh, Kuojen Tsao, Mary T. Austin, Stephen A. Fletcher, Suzanne M. Lopez, Kenneth J. Moise, Jr., Anthony Johnson and Ramesha Papanna
J. Clin. Med. 2020, 9(11), 3443; https://doi.org/10.3390/jcm9113443 - 27 Oct 2020
Viewed by 1976
Abstract
Maternal and pediatric delivery outcomes may vary in patients who underwent open fetal myelomeningocele repair and elected to deliver at the fetal center where their fetal intervention was performed versus at the referring physician’s hospital. A prospective cohort study of 88 patients were [...] Read more.
Maternal and pediatric delivery outcomes may vary in patients who underwent open fetal myelomeningocele repair and elected to deliver at the fetal center where their fetal intervention was performed versus at the referring physician’s hospital. A prospective cohort study of 88 patients were evaluated following in utero open fetal myelomeningocele repair at a single fetal center between the years 2011–2019. Exclusion criteria included patients that delivered within two weeks of the procedure (n = 6), or if a patient was lost to follow-up (n = 1). Of 82 patients meeting inclusion criteria, 36 (44%) patients were delivered at the fetal center that performed fetal intervention, and 46 (56%) were delivered locally. Comparative statistics found that with the exception of parity, baseline characteristics and pre-operative variables did not differ between the groups. No differences in oligohydramnios incidence, preterm rupture of membranes, gestational age at delivery or delivery indications were found. Patients who delivered with a referring physician were more likely to be multiparous (p = 0.015). With the exception of a longer neonatal intensive care unit (NICU) stay in the fetal center group (median 30.0 vs. 11.0 days, p = 0.004), there were no differences in neonatal outcomes, including wound dehiscence, cerebrospinal fluid leakage, patch management, ventricular diversion, or prematurity complications. Therefore, we conclude that it is safe to allow patients to travel home for obstetric and neonatal management after open fetal myelomeningocele repair. Full article
(This article belongs to the Special Issue New Prospects for Prenatal Diagnosis and Fetal Therapy)
Show Figures

Figure 1

13 pages, 1344 KiB  
Article
The Relevance of Fetal Abdominal Subcutaneous Tissue Recording in Predicting Perinatal Outcome of GDM Pregnancies: A Retrospective Study
by Friederike Weschenfelder, Nadin Baum, Thomas Lehmann, Ekkehard Schleußner and Tanja Groten
J. Clin. Med. 2020, 9(10), 3375; https://doi.org/10.3390/jcm9103375 - 21 Oct 2020
Cited by 2 | Viewed by 2819
Abstract
Guidelines on the management of gestational diabetes (GDM) instruct physicians to involve ultrasound-based monitoring of fetal growth in addition to blood glucose. So far, glucose control besides clinical parameters like maternal body mass index (BMI) and gestational weight gain have been shown to [...] Read more.
Guidelines on the management of gestational diabetes (GDM) instruct physicians to involve ultrasound-based monitoring of fetal growth in addition to blood glucose. So far, glucose control besides clinical parameters like maternal body mass index (BMI) and gestational weight gain have been shown to predict neonatal outcome. We aimed to evaluate the discriminative ability of fetal abdominal subcutaneous tissue (FAST) in addition to standard ultrasound parameters like abdominal circumference (AC) and estimated fetal weight (EFW) for perinatal complications like large for gestational age (LGA), hypoglycemia, hyperbilirubinemia, mode of delivery and admission to neonatal intensive care unit (NICU). Ultrasound data and neonatal outcome was collected of 805 GDM cases from 2012 to 2016: 3205 FAST, 3195 AC-measurements and 3190 EFW calculations were included. AC, EFW and FAST increased linear with gestational age. Combining ultrasound and clinical parameters improved predictive power for LGA. In the subgroup where fetuses grow with an AC > 75th additional adding of FAST to standard ultrasound parameters increased predictive power for hypoglycemia. Our results confirm inclusion of ultrasound parameters to be beneficial in monitoring GDM pregnancies. Additional FAST determination revealed to be of potential clinical relevance in the subgroup AC > 75th percentile. Full article
(This article belongs to the Special Issue New Prospects for Prenatal Diagnosis and Fetal Therapy)
Show Figures

Figure 1

8 pages, 4007 KiB  
Article
Foetal Sonographic Anogenital Distance Is Longer in Polycystic Ovary Syndrome Mothers
by Sharon Perlman, Yoel Toledano, Zvi Kivilevitch, Nufar Halevy, Elena Rubin and Yinon Gilboa
J. Clin. Med. 2020, 9(9), 2863; https://doi.org/10.3390/jcm9092863 - 4 Sep 2020
Cited by 12 | Viewed by 2708
Abstract
Anogenital distance (AGD) is a biomarker for the prenatal hormonal environment. Androgen excess is a key element in polycystic ovary syndrome (PCOS). The aim of this study was to assess the sonographic foetal AGD in a population of PCOS mothers in comparison to [...] Read more.
Anogenital distance (AGD) is a biomarker for the prenatal hormonal environment. Androgen excess is a key element in polycystic ovary syndrome (PCOS). The aim of this study was to assess the sonographic foetal AGD in a population of PCOS mothers in comparison to the general population. Foetal AGD was measured prospectively by 2D ultrasound in PCOS mothers and compared to prenatal AGD nomograms. The results were interpreted regarding maternal and foetal characteristics. The mean sonographic foetal AGD centile measurement in PCOS mothers was significantly longer in comparison to the general population (86.04% ± 18.22; p < 0.001). Estimated foetal weight and birthweight were appropriate for gestational age and did not correlate with AGD. Sonographic foetal AGD was significantly longer in PCOS diabetic mothers and in those who conceived following assisted reproduction treatments when compared to the general population (p < 0.001). Our results support the role of AGD as a biomarker of the prenatal hormonal environment and provide evidence for the hyperandrogenic effect in PCOS pregnancies on foetal androgenic status and genitalia development. Full article
(This article belongs to the Special Issue New Prospects for Prenatal Diagnosis and Fetal Therapy)
Show Figures

Graphical abstract

9 pages, 2682 KiB  
Article
The “No ARSA” Sign: A Novel Method of Prenatal Screening for Aberrant Right Subclavian Artery
by Eran Kassif, Abraham Tsur, Shir Shust-Barequet, Oshrat Raviv, Anya Kushnir, Samar Abu Snenh, Reuven Achiron, Shali Mazaki-Tovi, Boaz Weisz, Yishay Salem and Tal Weissbach
J. Clin. Med. 2020, 9(8), 2658; https://doi.org/10.3390/jcm9082658 - 17 Aug 2020
Cited by 1 | Viewed by 4715
Abstract
An aberrant right subclavian artery (ARSA) can be overlooked by the conventional method as described by Chaoui et al., due to acoustic shadowing. The aim of this study was to evaluate the feasibility and accuracy of a novel screening method for ARSA by [...] Read more.
An aberrant right subclavian artery (ARSA) can be overlooked by the conventional method as described by Chaoui et al., due to acoustic shadowing. The aim of this study was to evaluate the feasibility and accuracy of a novel screening method for ARSA by demonstrating the brachiocephalic artery bifurcation, referred to as the “No ARSA” sign. A prospective study conducted at a tertiary care center between 2018 and 2019 included unselected pregnant patients at a median gestational age of 15.1 (14.2–22.1; IQR (inter-quartile range)) weeks, who had been referred for a routine or targeted anomaly scan. All participants were scanned for the presence or absence of ARSA using both the conventional and the novel “No ARSA” methods for validation purposes. A total of 226 unselected patients were enrolled in the study. The “No ARSA” sign was visualized in 218 fetuses (96.5%). In the remaining 8 cases (3.5%), the “No ARSA” sign was not demonstrated. In these fetuses, an ARSA was visualized by the conventional method. The new method exhibited 100% feasibility and was in complete agreement with the conventional method. Intra- and inter-observer agreement was excellent (κ = 1). The results of the study suggest that the “No ARSA” sign is an efficient and reliable screening tool for ARSA. Full article
(This article belongs to the Special Issue New Prospects for Prenatal Diagnosis and Fetal Therapy)
Show Figures

Figure 1

12 pages, 237 KiB  
Article
Should We Report 15q11.2 BP1-BP2 Deletions and Duplications in the Prenatal Setting?
by Idit Maya, Sharon Perlman, Mordechai Shohat, Sarit Kahana, Shiri Yacobson, Tamar Tenne, Ifaat Agmon-Fishman, Reut Tomashov Matar, Lina Basel-Salmon and Rivka Sukenik-Halevy
J. Clin. Med. 2020, 9(8), 2602; https://doi.org/10.3390/jcm9082602 - 11 Aug 2020
Cited by 12 | Viewed by 3164
Abstract
Copy number variations of the 15q11.2 region at breakpoints 1-2 (BP1-BP2) have been associated with variable phenotypes and low penetrance. Detection of such variations in the prenatal setting can result in significant parental anxiety. The clinical significance of pre- and postnatally detected 15q11.2 [...] Read more.
Copy number variations of the 15q11.2 region at breakpoints 1-2 (BP1-BP2) have been associated with variable phenotypes and low penetrance. Detection of such variations in the prenatal setting can result in significant parental anxiety. The clinical significance of pre- and postnatally detected 15q11.2 BP1-BP2 deletions and duplications was assessed. Of 11,004 chromosomal microarray tests performed in a single referral lab (7596 prenatal, 3408 postnatal), deletions were detected in 66 cases: 39 in prenatal tests (0.51%) and 27 in postnatal tests (0.79%). Duplications were detected in 94 cases: 62 prenatal tests (0.82%) and 32 postnatal tests (0.94%). The prevalence of deletions and duplications among clinically indicated prenatal tests (0.57% and 0.9%, respectively) did not differ significantly in comparison to unindicated tests (0.49% and 0.78%, respectively). The prevalence of deletions and duplications among postnatal tests performed for clinical indications was similar to the prevalence in healthy individuals (0.73% and 1% vs. 0.98% and 0.74%, respectively). The calculated penetrance of deletions and duplications over the background risk was 2.18% and 1.16%, respectively. We conclude that the pathogenicity of 15q11.2 BP1-BP2 deletions and duplications is low. Opting out the report of these copy number variations to both clinicians and couples should be considered. Full article
(This article belongs to the Special Issue New Prospects for Prenatal Diagnosis and Fetal Therapy)
14 pages, 3038 KiB  
Article
The Diagnostic Accuracy of Magnetic Resonance Imaging for Maternal Acute Adnexal Torsion during Pregnancy: Single-Institution Clinical Performance Review
by Jong Hwa Lee, Hyun Jin Roh, Jun Woo Ahn, Jeong Sook Kim, Jin Young Choi, Soo-Jeong Lee and Sang Hun Lee
J. Clin. Med. 2020, 9(7), 2209; https://doi.org/10.3390/jcm9072209 - 13 Jul 2020
Cited by 8 | Viewed by 5054
Abstract
Background: For acute adnexal torsion of pregnant women, appropriate treatment based on an accurate diagnosis is especially important for fertility preservation and timely treatment. The 2017 American College of Obstetricians and Gynecologists (ACOG) Committee Opinion No. 723 announced its practice-changing guidelines to ensure [...] Read more.
Background: For acute adnexal torsion of pregnant women, appropriate treatment based on an accurate diagnosis is especially important for fertility preservation and timely treatment. The 2017 American College of Obstetricians and Gynecologists (ACOG) Committee Opinion No. 723 announced its practice-changing guidelines to ensure that diagnostic magnetic resonance imaging (MRI) conducted during the first trimester and gadolinium exposure at any time during pregnancy are safe for fetal stability. Unfortunately, few studies have been performed to evaluate the usefulness of the diagnostic accuracy of MRI for acute adnexal torsion during pregnancy. Objective: We sought to determine the efficacy of diagnostic MRI modality using multiparameter for maternal adnexal torsion during pregnancy. Methods: From 1 January 2007 to 31 January 2019, 131 pregnant with MRI tests were reviewed. In this retrospective cohort study, 94 women were excluded due to conditions other than an adnexal mass, and 37 were identified through MRI analyses conducted before surgery for suspected adnexal torsion. The primary outcome was the diagnostic accuracy of sonography and MRI, and the secondary outcome was the usefulness of Apparent diffusion coefficient (ADC) values for predicting the severity of hemorrhagic infarction between the medulla and cortex of the torsed ovarian parenchyma. Results: Our study demonstrates that in the diagnosis of adnexal torsion during pregnancy, the sensitivity, specificity, positive predictive value, and negative predictive value are 62.5%, 83.3%, 90.9%, and 45.5% for sonography and 100%, 77.8%, 90.5%, and 100% for MRI. MRI results in surgical-proven adnexal torsion patients revealed unilocular ovarian cysts (36.8% (7/19)), multilocular ovarian cysts (31.6% (6/19)), and near normal-appearing ovaries (31.6% (6/19)). Pathology in adnexal torsion revealed a corpus luteal ovarian cyst (63.2% (12/19)) and underlying adnexal pathology (46.8% (7/19)). Maternal adnexal torsion during pregnancy was more likely to occur in corpus luteal ovarian cysts than in underlying adnexal masses (odds ratio, 2.14; 95% confidence interval (CI), 0.428–10.738). MRI features for adnexal torsion were as follows: tubal wall thickness, 100% (19/19); ovarian stromal (medullary) edema, 100% (19/19); symmetrical or asymmetrical ovarian cystic wall, 100%(19/19); prominent follicles in the ovarian parenchyma periphery, 57.9% (11/19); periadenxal fat stranding, 84.2% (16/19); uterine deviation to the twisted side, 21.1% (4/19); and peritoneal fluid, 42.1% (8/19). The signal intensity of the ADC values of the ovarian medulla and cortex were compared between the cystectomy and detorsion (CD) and salpingo-oophorectomy (SO) groups. The ADC values of the CD and SO groups were 1.81 ± 0.09 × 10−3 mm2/s and 1.91 ± 0.18 × 10−3 mm2/s, respectively (P = 0.209), in the ovarian medulla and 1.37 ± 0.32 × 10−3 mm2/s and 0.96 ± 0.36 × 10−3 mm2/s, respectively (P = 0.022), in the ovarian cortex. The optimal cut-off value of ADC values for predictable total necrosis in the torsed ovarian cortex was ≤ 1.31 × 10−3 mm2/s (area under the curve (AUC) = 0.81; 95% CI 0.611–1.0; P = 0.028). Conclusion: Our data showed that maternal adnexal torsion during pregnancy occurred in most corpus luteal cystic ovary cases and some normal-appearing ovary during the 1st and 2nd trimesters of gestation. Therefore, this study is the first study to elaborate on the existence or usefulness of the diagnostic MRI for acute maternal adnexal torsion during pregnancy and to provide a predictive diagnosis of the severity of hemorrhagic infarction for deciding surgical radicality. Full article
(This article belongs to the Special Issue New Prospects for Prenatal Diagnosis and Fetal Therapy)
Show Figures

Figure 1

8 pages, 508 KiB  
Article
Nonimmune Hydrops Fetalis—Prenatal Diagnosis, Genetic Investigation, Outcomes and Literature Review
by Przemyslaw Kosinski, Pawel Krajewski, Miroslaw Wielgos and Aleksandra Jezela-Stanek
J. Clin. Med. 2020, 9(6), 1789; https://doi.org/10.3390/jcm9061789 - 8 Jun 2020
Cited by 8 | Viewed by 3418
Abstract
The aim of this paper is to review the outcomes and discuss the genetic and non-genetic aetiology of nonimmune hydrops fetalis in order to support differential ultrasound and genetic evaluations and family counselling. This single-centre study includes all cases of nonimmune hydrops fetalis [...] Read more.
The aim of this paper is to review the outcomes and discuss the genetic and non-genetic aetiology of nonimmune hydrops fetalis in order to support differential ultrasound and genetic evaluations and family counselling. This single-centre study includes all cases of nonimmune hydrops fetalis diagnosed prenatally from 2009 to 2019. Two sources of data were used for this study (prenatal and neonatal) to compare and summarise the findings. Data from genetic testing and ultrasound scans were collected. In total, 33 pregnant women with prenatally diagnosed nonimmune hydrops fetalis were studied. The data included 30 cases of singleton (91%) and three cases (9%) of twin pregnancies. There were 14 survivors (43%), seven cases of postnatal deaths (21%), four cases of intrauterine foetal demises (12%), four cases of termination of pregnancy (12%), and four women without a follow up (12%). The total number of chromosomally normal singleton pregnancies was 29 (88%), and 14 foetuses had an anatomical abnormality detected on the ultrasound scan. The chance of survival was the highest in cases of isolated, idiopathic hydrops fetalis, which in most cases was due to an undetectable intrauterine infection. In many cases, the diagnosis could not be established throughout pregnancy. Each case of nonimmune hydrops fetalis should thus be analysed individually. Full article
(This article belongs to the Special Issue New Prospects for Prenatal Diagnosis and Fetal Therapy)
Show Figures

Figure 1

Back to TopTop